Serotype distribution and antimicrobial susceptibility of group B streptococci in pregnant women: Results from a Swiss tertiary centre

Swiss Medical Weekly

Volumn 144, Issue , 2014, Pages

  Fröhlicher, Simone ^a   Reichen, Gabriela ^a   Müller, Martin ^b   Surbek, Daniel ^b   Droz, Sara ^a   Spellerberg, Barbara ^c   Sendi, Parham ^a,b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Antimicrobial susceptibility; Group B streptococcus; Maternal GBS colonisation

Indexed keywords

CLINDAMYCIN; ERYTHROMYCIN; PENICILLIN DERIVATIVE; ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; ASIA; BACTERIAL COLONIZATION; BACTERIUM ISOLATE; DISK DIFFUSION; EPSILOMETER TEST; ETHNICITY; FEMALE; HUMAN; LATEX AGGLUTINATION TEST; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POLYMERASE CHAIN REACTION; PREGNANT WOMAN; PROSPECTIVE STUDY; SEROTYPE; STREPTOCOCCUS AGALACTIAE; SWITZERLAND; ASIAN; DRUG EFFECT; HETEROZYGOTE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; PENICILLIN RESISTANCE; PERINEUM; PREGNANCY; PREGNANCY COMPLICATION; SEROTYPING; STREPTOCOCCUS INFECTION; TERTIARY CARE CENTER; UTERINE CERVIX; VAGINA; YOUNG ADULT;

ADULT; ANTI-BACTERIAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CARRIER STATE; CERVIX UTERI; CLINDAMYCIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ERYTHROMYCIN; FEMALE; HUMANS; MICROBIAL SENSITIVITY TESTS; PENICILLIN RESISTANCE; PENICILLINS; PERINEUM; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PROSPECTIVE STUDIES; SEROTYPING; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS AGALACTIAE; SWITZERLAND; TERTIARY CARE CENTERS; VAGINA; YOUNG ADULT;

EID: 84899734511     PISSN: 14247860     EISSN: 14243997     Source Type: Journal    
DOI: 10.4414/smw.2014.13935     Document Type: Article

References (38)

1. Baker CJ, Barrett FF. Transmission of group B streptococci among parturient women and their neonates. The Journal of pediatrics. 1973;83:919-25.
2. Barcaite E, Bartusevicius A, Tameliene R, Kliucinskas M, Maleckiene L, Nadisauskiene R. Prevalence of maternal group B streptococcal colonisation in European countries. Acta obstetricia et gynecologica Scandinavica. 2008;87:260-71. (Pubitemid 351317488)
3. Rausch AV, Gross A, Droz S, Bodmer T, Surbek DV. Group B Streptococcus colonization in pregnancy: prevalence and prevention strategies of neonatal sepsis. J Perinat Med. 2009;37:124-9.
4. Anthony BF. Carriage of group B streptococci during pregnancy: a puzzler. The J Infect Dis. 1982;145:789-93. (Pubitemid 12088952)
5. Renner RM, Renner A, Schmid S, Hoesli I, Nars P, Holzgreve W, et al. Efficacy of a strategy to prevent neonatal early-onset group B streptococcal (GBS) sepsis. J Perinat Med. 2006;34:32-8. (Pubitemid 43106296)
6. Verani JR, McGee L, Schrag SJ. Prevention of perinatal group B streptococcal disease - revised guidelines from CDC, 2010. MMWR. Recommendations and reports: Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control. 2010;59:1-36.
7. Schrag SJ, Zywicki S, Farley MM, Reingold AL, Harrison LH, Lefkowitz LB, et al. Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. N Engl J Med. 2000;342:15-20. (Pubitemid 30020655)
8. Dahesh S, Hensler ME, Van Sorge NM, Gertz RE, Jr., Schrag S, Nizet V, et al. Point mutation in the group B streptococcal pbp2x gene conferring decreased susceptibility to beta-lactam antibiotics. Antimicrob Agents Chemother. 2008;52:2915-8.
9. Kimura K, Suzuki S, Wachino J, Kurokawa H, Yamane K, Shibata N, et al. First molecular characterization of group B streptococci with reduced penicillin susceptibility. Antimicrob Agents Chemother. 2008;52:2890-7.
10. Gaudreau C, Lecours R, Ismail J, Gagnon S, Jette L, Roger M. Prosthetic hip joint infection with a Streptococcus agalactiae isolate not susceptible to penicillin G and ceftriaxone. J antimicrob Chemother. 2010;65:594-5.
11. Longtin J, Vermeiren C, Shahinas D, Tamber GS, McGeer A, Low DE, et al. Novel mutations in a patient isolate of Streptococcus agalactiae with reduced penicillin susceptibility emerging after long-term oral suppressive therapy. Antimicrob Agents Chemother. 2011;55:2983-5.
12. Murdoch DR, Reller LB. Antimicrobial susceptibilities of group B streptococci isolated from patients with invasive disease: 10-year perspective. Antimicrobial agents and chemotherapy. 2001;45:3623-4. (Pubitemid 33107892)
13. Fernandez M, Hickman ME, Baker CJ. Antimicrobial susceptibilities of group B streptococci isolated between 1992 and 1996 from patients with bacteremia or meningitis. Antimicrobial agents and chemotherapy. 1998;42:1517-9. (Pubitemid 28257664)
14. Garland SM, Cottrill E, Markowski L, Pearce C, Clifford V, Ndisang D, et al. Antimicrobial resistance in group B streptococcus: the Australian experience. J Med Microbiol. 2011;60:230-5.
15. DiPersio LP, DiPersio JR. High rates of erythromycin and clindamycin resistance among OBGYN isolates of group B Streptococcus. Diagn Microbiol Infect Dis. 2006;54:79-82. (Pubitemid 41815192)
16. von Both U, Ruess M, Mueller U, Fluegge K, Sander A, Berner R. A serotype V clone is predominant among erythromycin-resistant Streptococcus agalactiae isolates in a southwestern region of Germany. Journal of clinical microbiology. 2003;41:2166-9. (Pubitemid 36576556)
17. von Both U, Buerckstuemmer A, Fluegge K, Berner R. Heterogeneity of genotype-phenotype correlation among macrolide-resistant Streptococcus agalactiae isolates. Antimicrobial agents and chemotherapy. 2005;49:3080-2. (Pubitemid 40917647)
18. Manning SD, Foxman B, Pierson CL, Tallman P, Baker CJ, Pearlman MD. Correlates of antibiotic-resistant group B streptococcus isolated from pregnant women. Obstet Gynecol. 2003;101:74-9. (Pubitemid 36061258)
19. Lin FY, Azimi PH, Weisman LE, Philips JB, 3rd, Regan J, Clark P, et al. Antibiotic susceptibility profiles for group B streptococci isolated from neonates, 1995-1998. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2000;31:76-9.
20. Uh Y, Kim HY, Jang IH, Hwang GY, Yoon KJ. Correlation of serotypes and genotypes of macrolide-resistant Streptococcus agalactiae. Yonsei Med J. 2005,46:480-3. (Pubitemid 41283057)
21. EUCAST. Clinical Breakpoint Table v. 3,1. European Commitee on Antimicrobial Susceptibility Testing.
22. Woods CR. Macrolide-inducible resistance to clindamycin and the Dtest. Pediatr Infect Dis J. 2009;28:1115-8.
23. EUCAST. Expert rules. European Commitee on Antimicrobial Susceptibility Testing
24. Slotved HC, Elliott J, Thompson T, Konradsen HB. Latex assay for serotyping of group B Streptococcus isolates. Journal of clinical microbiology. 2003;41:4445-7. (Pubitemid 37099727)
25. Kong F, Gowan S, Martin D, James G, Gilbert GL. Serotype identification of group B streptococci by PCR and sequencing. Journal of clinical microbiology. 2002;40:216-26. (Pubitemid 34027627)
26. Arpin C, Daube H, Tessier F, Quentin C. Presence of mefA and mefE genes in Streptococcus agalactiae. Antimicrob Agents Chemother.1999;43:944-6. (Pubitemid 29165763)
27. Berkowitz K, Regan JA, Greenberg E. Antibiotic resistance patterns of group B streptococci in pregnant women. Journal of clinical microbiology. 1990;28:5-7. (Pubitemid 20016767)
28. de Azavedo JC, McGavin M, Duncan C, Low DE, McGeer A. Prevalence and mechanisms of macrolide resistance in invasive and noninvasive group B streptococcus isolates from Ontario, Canada. Antimicrobial agents and chemotherapy. 2001;45:3504-8. (Pubitemid 33107869)
29. Capanna F, Emonet SP, Cherkaoui A, Irion O, Schrenzel J, Martinez de Tejada B. Antibiotic resistance patterns among group B Streptococcus isolates: implications for antibiotic prophylaxis for early-onset neonatal sepsis. Swiss Med Wkly. 2013;143:w13778.
30. Patel M, Waites KB, Moser SA, Cloud GA, Hoesley CJ. Prevalence of inducible clindamycin resistance among community- and hospital-associated Staphylococcus aureus isolates. Journal of clinical microbiology. 2006;44:2481-4. (Pubitemid 44092415)
31. Drinkovic D, Fuller ER, Shore KP, Holland DJ, Ellis-Pegler R. Clindamycin treatment of Staphylococcus aureus expressing inducible clindamycin resistance. J Antimicrob Chemother. 2001;48:315-6. (Pubitemid 32755300)
32. Siberry GK, Tekle T, Carroll K, Dick J. Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2003;37:1257-60.
33. Lewis JS, 2nd, Jorgensen JH. Inducible clindamycin resistance in Staphylococci: should clinicians and microbiologists be concerned? Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2005;40:280-5.
34. Desjardins M, Delgaty KL, Ramotar K, Seetaram C, Toye B. Prevalence and mechanisms of erythromycin resistance in group A and group B Streptococcus: implications for reporting susceptibility results. Journal of clinical microbiology. 2004;42:5620-3. (Pubitemid 40003766)
35. Sendi P, Johansson L, Norrby-Teglund A. Invasive group B Streptococcal disease in non-pregnant adults: a review with emphasis on skin and soft-tissue infections. Infection. 2008;36:100-11.
36. Chohan L, Hollier LM, Bishop K, Kilpatrick CC. Patterns of antibiotic resistance among group B streptococcus isolates: 2001-2004. Infectious diseases in obstetrics and gynecology. 2006;2006:57492.
37. Wang H, Zhao CJ, He WQ, Zhang FF, Zhang LY, Cao B, et al. High Prevalence of Fluoroquinolone-Resistant Group B Streptococci among Clinical Isolates in China and Predominance of Sequence Type 19 with Serotype III. Antimicrobial Agents and Chemotherapy. 2013;57:1538-41.
38. Back EE, O'Grady EJ, Back JD. High rates of perinatal group B Streptococcus clindamycin and erythromycin resistance in an upstate New York hospital. Antimicrob Agents Chemother. 2012;56:739-42.